Monoclonal Antibodies for Prophylaxis and Treatment of Respiratory Viral Infections
- Jim Boonyaratanakornkit; Michael Boeckh; Alpana Waghmare
 
Access Resources
About
                This article discusses the use of monoclonal antibodies (mAbs) to prevent and treat respiratory viral infections, especially in people with weak immune systems. It describes how mAbs have been developed quickly during the COVID-19 pandemic. Some new mAbs have been approved for early COVID-19 treatment but faced challenges due to virus variants. The article highlights ways to improve mAb effectiveness, like extending their lifespan in the body. It also mentions that more mAbs are being developed for viruses like SARS-CoV-2 and RSV, expecting continued growth in available treatments.
              
            Tags
More like this
            The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.